Xbiotech announces enrollment completion of phase ii, placebo controlled, multicenter study for natrunix in pancreatic cancer

Austin, texas, aug. 30, 2023 (globe newswire) -- xbiotech inc. announced today completion of enrollment of the phase ii portion of its 1-better study—a phase i/ii randomized, double-blind, placebo-controlled clinical study for natrunix in combination with chemotherapy for treating pancreatic cancer.

XBIT Ratings Summary

XBIT Quant Ranking